Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation

Completed
Conditions
Interventions
First Posted Date
2021-01-11
Last Posted Date
2024-11-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
108
Registration Number
NCT04702893
Locations
🇩🇪

Universitätsklinikum Aachen, AöR, Aachen, Germany

🇩🇪

Pneumologische Praxis Dr. Löh, Bad Homburg, Germany

🇩🇪

Vivantes Klinikum Neukölln, Berlin, Germany

and more 18 locations

A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis

Phase 2
Withdrawn
Conditions
Interventions
First Posted Date
2020-12-23
Last Posted Date
2021-11-08
Lead Sponsor
Boehringer Ingelheim
Registration Number
NCT04680676

A Study in Healthy People to Test Whether BI 730357 Influences the Amount of Caffeine, Warfarin, Omeprazole, and Midazolam in the Blood

First Posted Date
2020-12-22
Last Posted Date
2023-08-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
16
Registration Number
NCT04679948
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece

First Posted Date
2020-12-17
Last Posted Date
2024-06-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1396
Registration Number
NCT04672941
Locations
🇬🇷

Metropolitan Hospitsal, PNOI Pulmonology Clinic, Athens, Greece

🇬🇷

European Interbalkan Medical Center, Pulmonology Clinic, Thessaloniki, Greece

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

Phase 2
Completed
Conditions
Interventions
First Posted Date
2020-12-14
Last Posted Date
2023-11-02
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
387
Registration Number
NCT04667377
Locations
🇺🇸

Valley Weight Loss Clinic, Fargo, North Dakota, United States

🇦🇺

Nepean Hospital, Kingswood, New South Wales, Australia

🇺🇸

Lucas Research, Inc., Morehead City, North Carolina, United States

and more 40 locations

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 764198 Are Tolerated

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-12-14
Last Posted Date
2021-11-01
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
44
Registration Number
NCT04665700
Locations
🇯🇵

SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 765080

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-12-14
Last Posted Date
2024-02-23
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
48
Registration Number
NCT04666922
Locations
🇧🇪

SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation

First Posted Date
2020-12-07
Last Posted Date
2024-11-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
7
Registration Number
NCT04656275
Locations
🇩🇪

IKF Pneumologie GmbH & Co. KG, Frankfurt, Germany

🇩🇪

Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH, Großhansdorf, Germany

🇩🇪

KLB Gesundheitsforschung Lübeck GmbH, Lübeck, Germany

A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood

First Posted Date
2020-12-07
Last Posted Date
2021-03-22
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
28
Registration Number
NCT04656288
Locations
🇧🇪

SGS Belgium NV Research Unit Stuivenberg, Antwerpen, Belgium

© Copyright 2024. All Rights Reserved by MedPath